www.alk.net
  • Your allergy
    • What is allergy
      • House dust mite allergy
      • Pollen allergy
      • Living with allergy
      • Socio-economic impact
    • What is allergic asthma
    • How is allergy diagnosed
    • Treating allergy
  • Our solutions
    • Consumer healthcare
    • Diagnostics
    • Allergy vaccines
      • Production
    • Emergency medicine
  • Our science
    • Scientific focus
    • Science & technology
    • Pipeline
    • Digital innovation
    • Clinical data sharing
    • Collaboration & partnerships
    • Healthcare Professionals
      • Allergy Immunotherapy
      • Reweal
      • Clinical trials
      • Webinars
      • The Henning Lowenstein Research Award
  • Our company
    • Press
    • Our strategy
    • Our leadership
    • Our history
    • Corporate governance
  • Sustainability
  • Investors
    • Overview
    • Financial reporting
      • Risk management
      • Reporting standards
      • Auditors
    • Governance
      • Executive Leadership Team
      • Board of Directors
    • News & Events
      • Company Releases
      • Company releases (DK)
      • Webcasts & presentations
      • Investor calendar
      • Capital Markets Day 2024
    • The Share
      • Dividend history
      • Analyst coverage
      • Analyst estimates
      • Shareholder information
      • Authorizations
    • Contact IR
    • Annual general meeting
      • Annual general meeting (DK)
    • Capital Markets Day 2024
  • Careers
    • Working at ALK
    • Vacant positions
    • Cultural Beliefs
  • Select country
Search

Shareholder information

Links: 
Dividend history
Analyst coverage
Analyst estimates
Shareholder information
Authorizations

The share capital of the Company has a total nominal value of DKK 111,411,960, of which DKK 9,207,600 is in A shares, DKK 920,760 is in AA-shares and DKK 101,283,600 is in B shares.

The Company’s share capital is divided into shares with a nominal value of DKK 0.50 each. Each A share of DKK 0.50 nominal value carries ten votes, each AA share of DKK 0.50 nominal value carries ten votes, and each B share of DKK 0.50 nominal value carries one vote.

Ownership

On 31 December 2025, ALK had 34,777 registered shareholders versus 37,215 at the end of 2024. The registered shareholders owned 98.4% of the share capital (97.8%).

One shareholder has reported to ALK that they held 5% or more of the shares on 31 December 2025:

The Lundbeck Foundation (Copenhagen, Denmark): 40.3% incl. A and AA shares.

Most large, registered shareholders were institutional investors, mainly in Denmark, other European countries, and North America.

To meet obligations to deliver shares under management incentive programmes, ALK held 1,261,283 of its own shares, or 0.6% of the share capital, similar to the end of 2024.

The Board of Directors and Board of Management held a total of 65,930 shares at year-end, corresponding to less than 0.1% of the share capital (<0.1%).

 

Shareholders and treasury shares as at 31 December 2025
 

The Lundbeck Foundation

Registered office: Copenhagen, Denmark

A shares, number: 18,414,400

AA shares, number: 1,841,440

B shares number: 69,496,540

Interest: 40.3%

Votes: 67.2%

 

ALK – treasury shares

Registered office: Hørsholm, Denmark

B shares, number: 1,261,283 B shares

Interest: 0.6%

 

Other

A shares, number: 800

AA shares, number: 80

B shares number: 131,743,447

Interest: 59%

Votes: 32.7%

 
  • Email Alerts

    Email Alerts

  • Downloads

    Downloads

  • RSS

    RSS

  • Print

    Print

  • Share

    Share

  • English

    English

  • Search

    Search




Select Country Menu

  • Change Country

Quick Links

  • Contact us
  • News
  • Media
  • Vacant jobs
  • Products

ALK Footer Copyright Text

ALK-Abelló A/S ∙ Bøge Allé 6 ∙ DK-2970 Hørsholm ∙ Denmark ∙ CVR no. 63717916 ∙ T +45 45 74 75 76 Legal disclaimer © ALK ∙ All rights reserved